groups such as the Bantu in whom coronary insufficiency is almost unknown have significantly lower levels of serum lipoprotein than do agematched Europeans (Walker & Arvidsson 1954 , Bronte-Stewart et al. 1955 . Also within one racial group, living in the same environment, individuals with a high lipoprotein level are more prone to coronary heart disease than those with a lower level (Dawber et al. 1962 ). It has not yet been shown how a high circulating level of lipoprotein can lead to atherosclerosis and thrombosis but one hypothesis put forward is that lipoprotein inhibits spontaneous fibrinolysis (Greig 1956 , Kwaan & McFadzean 1957) . It is believed that coagulation is going on continuously within the circulation, the fibrinogen molecule being converted to fibrin which is then removed by the fibrinolytic system; thus, if fibrinolytic activity is depressed intravascular fibrin will persist and become incorporated into the arterial wall, leading to stenosis and occlusion (Astrup 1956 ).
In normal circulating plasma, spontaneous fibrinolysis is thought to result from the interaction of plasminogen, activator, plasmin and antiplasmins. The inactive pro-enzyme plasminogen is converted to plasmin by an activator which is released from endothelium. This activator is always present in circulating plasma and is increased in response to certain stimuli of which exercise, anxiety, adrenaline injection and local ischimia are the best known. Plasmin, which is the actual fibrinolytic enzyme, does not normally exist free in plasma, the small amounts which may be formed being inactivated by inhibitors called antiplasmins. The removal of intravascular fibrin is thought to occur by the following mechanism: as fibrinogen is converted to fibrin, plasminogen and activator are adsorbed on to the fibrin molecule; activator in plasma surrounding the clot is also adsorbed on to the fibrin surface and some activator diffuses into the thrombus. On the fibrin surface plasminogen and activator react together so that plasmin is formed in intimate contact with the fibrin molecule. In this situation plasmin is at least partially protected from the antiplasmins and, by this induced substrate specificity, the fibrin to which it is adsorbed is lysed (Fearnley 1961 (Howell 1964) . Comparisons of Bantus and Europeans (Franz et al. 1961 , Merskey et al. 1960 , Walker 1961 , and New Guinea natives and Europeans (Goldbrick 1961) Kwaan & McFadzean (1957) described the effect of raised serum cholesterol upon the lysis of thrombi in rabbits. Thrombi artificially induced in the marginal ear veins of rabbits normally disappear spontaneously and the vein when examined histologically is found to be normal: however, when thrombi were induced in rabbits which had been fed on cholesterol for ten days it took significantly longer for recanalization to occur and histological examination of the vein showed some organization of thrombus.
In another paper, the effect of alimentary lipmmia upon lysis of thrombi induced in the jugular veins of dogs was described by Bang & Cliffton (1960) . As such thrombi do not lyse spontaneously, an intravenous infusion of a fibrinolytic enzyme was given two hours after their formation. One group of animals were fasting when thrombi were formed and in these complete lysis occurred during the five hours the infusion lasted, but in a second group in which thrombi were formed during lipxemia following the ingestion of cream, thrombi were not lysed and subsequent histological examination showed strands of fibrin embedded in and surrounded by fat. A similar experiment upon dogs was carried out by Furata in 1962 and this also showed lysis ofjugular thrombi to be inhibited by lipwmia due to ingestion of saturated fat. In these experiments inhibition could have been at any of th-e points in the fibrinolytic system to which I have referred.
The remainder of the work on lipoproteins and fibrinolysis will be reviewed by discussing experimental findings in relation to each point at which inhibition is possible.
( saturated fat has no effect upon euglobulin lysis time and therefore no effect upon plasminogen activation. This is in agreement with the work of Buckell & Elliot (1959) and Lackner & SouginMibashan (1961) , and Gajewski (1961) Kommerell & Berger (1959) and Cliffton & Burchell (1961) have published work suggesting that the ingestion of saturated fat enhances the inhibitory factors of the fibrinolytic system. All the experiments discussed above would give an indication of any direct interference with the proteolysis of fibrin, as the actual lysis of a clot ultimately depends upon the lysis of fibrin by plasmin. The possibility that lipoproteins may inhibit plasmin by potentiating antiplasmin activity must, however, be considered separately because in clot lysis experiments, antiplasmin activity is either entirely absent or greatly reduced by dilution. In vitro studies have not revealed such a potentiation of antiplasmin activity; the inhibition of lysis which is brought about when serum is included in a clot is not affected by the removal of 5-lipoprotein from the serum, nor does the presence of chylomicrons affect the inhibition (Howell 1964 ).
(4) The Effect ofLipoprotein upon the Adsorption ofActivator andPlasminogen to Fibrin and the Di/jusion ofActivator into the Clot Very little work has been done which specifically deals with these possibilities, although the observation of Bang & Cliffton (1960) that the strands of fibrin in the jugular thrombi of their dogs were embedded in fat does suggest that lipoprotein may physically block the enzyme from the fibrin surface. However, in vitro studies in which clots were floated in fibrinolytic enzymes have shown that the presence of quite large quantities of chylomicrons or 5-lipoprotein in the clot does not affect speed or degree of lysis (Howell 1964, in preparation) .
Conclusion
Consideration of the mechanism of in vivo lysis of fibrin suggests that it is possible for inhibition to operate at any of a number of points; review of experimental findings does not reveal at which of these inhibition due to raised serum lipoprotein level occurs. In spite of this, the fact that in vivo lysis of thombi has been prevented by raising circulating lipoprotein level does suggest strongly that fibrinolysis is inhibited by lipoprotein, even though such inhibition has not been reproduced in vitro. Results of comparative studies of fibrinolytic activity in racial groups having differing 5-lipoprotein levels merit further comparison: this should be made between people with differing 5-lipoprotein levels who are of the same racial group and living in the same environment.
In recent years there has been much interest in the fibrinolytic enzyme system, in large part stimulated by the availability of fibrinolytic enzymes for therapeutic trial. There has been a limited interest in fibrinolysis over the last thirty years, but as so often happens no great general attention was paid to this aspect of research until it emerged that the fibrinolytic enzyme system could be exploited to remove intravascular deposits of fibrin. It must be made clear from the outset that it is unlikely that thrombolytic enzymes will solve the numerous problems associated with the intravascular deposition of fibrin and that this treatment is still in the clinical investigative stage. The present indications for the use of fibrinolytic agents are strictly limited. Observations in patients given such enzymes have, however, greatly increased understanding of the physiology and pathology of the fibrinolytic enzyme system and it may be that from such work will arise the possibility of prophylaxis of thrombosis rather than its treatment when established. There is evidence that the system is constantly active under physiological circumstances and it may be that the important therapeutic goal will be the discovery of an agent capable of increasing the normal background of physiological fibrinolytic activity. (Albrechtsen 1957) . Plasma plasminogen activator, which is present in trace amounts in normal plasma, is found in increased amount after exercise, and after injection of adrenaline, pyrogens, nicotinic acid and other non-enzymatic agents. One site of production of plasma activator is probably the walls of veins with local anoxia as an important stimulus (Kwaan & McFadzean 1956 , Todd 1959 .
Other activators of current interest are urokinase, streptokinase and staphylokinase. Streptokinase is produced by the hoemolytic streptococcus and was the first activator to be identified (Tillett & Garner 1933) . Urokinase is the physiological plasminogen activator present in normal urine and may represent, in part at least, excreted plasma activator. Plasmin once produced in small amounts from plasminogen can, by an autocatalytic effect, activate more plasminogen.
The measurement of activators is an important aspect of laboratory studies on fibrinolysis. Unfortunately, rapid simple assay systems are not available. The plasminogen-enriched '311-labelled clot system is excellent as a research method but is too complex for routine control of thrombolytic therapy. In this technique fibrinogen is tracelabelled with 1311, enriched with plasminogen and clotted round a wire spiral. Activator is measured by the release of radioactivity (Alkjaersig et al. 1959 , McNicol et al. 1962 ). The fibrin plate assay also measures the ability to lyse fibrin, but it requires overnight incubation and so is unsuitable for concurrent control of therapy; the area of lysis
